Samsung Bioepis Enters into a Strategic Partnership with NIPRO for Commercialization of Multiple Biosimilars in Japan
INCHEON, Korea--(BUSINESS WIRE)--Jun 8, 2025--
Samsung Bioepis Co., Ltd. ('Samsung Bioepis') announced today that the company has entered into a license, development and commercialization agreement with NIPRO Corporation ('NIPRO') for multiple biosimilar candidates including SB17, ustekinumab biosimilar candidate, in Japan.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250608582351/en/
Samsung Bioepis (President and CEO: Kyung-Ah Kim) has entered into a license, development and commercialization agreement with NIPRO Corporation (President: Yoshihiko Sano) for multiple biosimilar candidates in Japan.
Under the terms of the agreement, Samsung Bioepis will be responsible for the development, manufacture and supply of the medicines, while NIPRO will be responsible for commercialization of the medicines in Japan.
'This partnership marks an important step towards expanding our footprint in Japan. Biosimilars have a great potential to bring cost savings and widen access to treatments for healthcare systems, providers, and patients in Japan. We look forward to collaborating with NIPRO, a company renowned for its high-quality medical devices and healthcare solutions, to accelerate access to treatments in the Japanese market,' said Kyung-Ah Kim, President and Chief Executive Officer of Samsung Bioepis. 'We will continue to advance our development platform and innovate access to treatments for healthcare systems, payers, physicians, and patients around the world.'
About Samsung Bioepis Co., Ltd.
Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, and endocrinology. For more information, please visit: www.samsungbioepis.com and follow us on social media – LinkedIn, X.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250608582351/en/
CONTACT: MEDIA CONTACT
Anna Nayun Kim,[email protected]
Yoon Kim,[email protected]
KEYWORD: SOUTH KOREA JAPAN ASIA PACIFIC
INDUSTRY KEYWORD: SCIENCE BIOTECHNOLOGY RESEARCH PHARMACEUTICAL GENERAL HEALTH HEALTH CLINICAL TRIALS OTHER HEALTH
SOURCE: Samsung Bioepis Co., Ltd.
Copyright Business Wire 2025.
PUB: 06/08/2025 08:00 PM/DISC: 06/08/2025 07:58 PM
http://www.businesswire.com/news/home/20250608582351/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
19 minutes ago
- Bloomberg
Chinese Stocks in Hong Kong Head for Bull Market Before US Talks
Chinese shares trading in Hong Kong were on course to enter a bull market by Monday's close, as planned talks between the US and China fuel a wider sense of relief among investors. The Hang Seng China Enterprises Index rose as much as 1.7%, putting it on track to close more than 20% higher than its low on April 7. Technology and e-commerce shares led gains, helping the gauge outperform a 0.9% bounce in the MSCI Asia Pacific Index.
Yahoo
31 minutes ago
- Yahoo
The cost of caring for a loved one
It's Carers' Week, when we're encouraged to recognise the effort put in by unpaid carers looking after their loved ones. As more people live longer and need more care, it should also be a chance to consider what we'd do if we found ourselves in this position, and someone we love needed care. You might want to step in and help, so it's worth understanding the potential costs — from the extras you'd need at home to the cost of any lost income. In many cases, the whole family will need to have a frank conversation about how to support the person offering care, as well as the person needing it. If your family member needs professional care, the question of costs becomes even more pressing. On average, you'll pay about £50,000 a year for residential care and £66,000 for a nursing home, but the averages hide some big costs, and plenty of people pay well over £100,000 a year. You may be able to get some help from the state, but there's a process you need to go through first. It starts with a "needs assessment", done by your local authority, who will work out what care the person needs. Read more: How much does it cost to become a driver in the UK? Next you go through a financial assessment, which looks at the assets of the person needing care. If they're getting care at home, or they're in a care home temporarily, this assessment won't include the value of their own home. If they're going into a care home permanently, it may include their home, unless someone from specific groups also lives there. This includes a partner, any of their children under the age of 18, or a relative who is disabled or over the age of 60. In England, if they have assets of less than £14,250, the council may pay for care — although it will also take their income into account. If they have between £14,250 and £23,250, they will have to contribute to the cost of care, but if they have assets over £23,250, they'll need to foot the entire bill. If your loved one has complex medical needs, they should be assessed for NHS Continuing Healthcare. This can pay for all their care in some cases, but don't assume they'll qualify. It's not enough to have caring needs around the clock, they'll have to have very high medical needs too, requiring regular intervention from medical experts and professionals. If you end up needing to pay for care for someone, there are a few benefits that will help. If they are over state pension age, they could get the attendance allowance — or pension age disability in Scotland. However, this will barely scratch the surface of costs. It means you may need to speak to anyone in your life who might need care, to see what preparations they've put in place. A piece of research we did a while ago found that fewer than half of people thought their loved ones could pay for care from their savings. It means you should consider their pension too. A guaranteed monthly pension income will go towards the cost of care. If they're using pension drawdown, they may have money in their pension pot that can be used too. For younger people, this often makes sense as a way to save for your own care needs, especially if you're saving into a workplace pension and your employer is helping to build the pot. Read more: What is the Pension Investment Review? However, the value of the property will often need to be used. Some people will rent the family home out to cover fees, although this is risky because rental income isn't guaranteed, and will be depleted by maintenance and repairs. You can consider equity release to free up some of the value in the property, but this is expensive. There will be a set up cost, and usually any interest on the loan will roll up, and needs to repaid when the property is sold. There's also the option of a deferred payment arrangement with the local council, which is a bit like equity release, but run by the council and slightly less expensive. But for many people, the most sensible option ends up being selling up. You might pay fees from the lump sum as you go along, but it's worth considering an immediate needs care annuity instead. These pay a fixed amount to the care home every month for the rest of their life, and tend to cover the gap between pension income and the cost of care. Talking to your loved ones about care, and how they'd pay for it, is difficult, but it's a far easier conversation well in advance, when they have time to make a plan. It's much more stressful to try to discuss this at the point they already need care and are starting to panic about how they're going to pay for more: How to tell if you're rich Should people keep working until later in life? How to get your children to move outError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
40 minutes ago
- Yahoo
Undiscovered Gems in Asia To Watch This June 2025
As global markets navigate a complex landscape marked by cooling U.S. labor markets and fluctuating manufacturing indices, small-cap stocks have emerged as leaders, with the Russell 2000 Index showing notable gains. In this dynamic environment, identifying promising small-cap opportunities in Asia requires a keen understanding of market conditions and an eye for companies that demonstrate resilience and potential for growth amidst economic shifts. Name Debt To Equity Revenue Growth Earnings Growth Health Rating Wuxi Chemical Equipment NA 13.24% -0.17% ★★★★★★ Anji Foodstuff NA 9.26% -13.65% ★★★★★★ Shantou Institute of Ultrasonic Instrument NA 17.40% 16.47% ★★★★★★ Shenzhen Zhongheng Huafa NA 1.77% 31.72% ★★★★★★ Nanfang Ventilator NA -11.92% 6.62% ★★★★★★ CMC 1.18% 2.73% 9.22% ★★★★★☆ Hyakugo Bank 170.58% 6.26% 7.74% ★★★★★☆ BIOBIJOULtd 6.87% 72.99% 117.16% ★★★★★☆ Li Ming Development Construction 158.65% 19.65% 25.78% ★★★★☆☆ Keli Motor Group 35.39% 9.99% -14.86% ★★★★☆☆ Click here to see the full list of 2605 stocks from our Asian Undiscovered Gems With Strong Fundamentals screener. Here we highlight a subset of our preferred stocks from the screener. Simply Wall St Value Rating: ★★★★★☆ Overview: GT Gold Holdings Limited is an investment holding company focused on the exploration, mining, and processing of gold deposits in the People's Republic of China, with a market cap of HK$3.05 billion. Operations: GT Gold Holdings generates revenue primarily from its gold mining operations, amounting to HK$1.18 billion. GT Gold Holdings shines with its impressive earnings growth of 159.5% over the past year, outpacing the Metals and Mining industry average of 43%. The company has reduced its debt to equity ratio significantly from 145.8% to a more manageable 28.9% in five years, showcasing prudent financial management. Despite a drop in net profit margin from last year's 14.8% to 5.2%, their interest payments are well-covered by EBIT at a solid coverage of 5.8x, indicating robust operational performance amidst challenges like a HK$37M one-off gain impacting recent results. Take a closer look at GT Gold Holdings' potential here in our health report. Review our historical performance report to gain insights into GT Gold Holdings''s past performance. Simply Wall St Value Rating: ★★★★☆☆ Overview: UOB-Kay Hian Holdings Limited is an investment holding company that offers services such as stockbroking, futures broking, structured lending, investment trading, margin financing, and nominee and research services with a market capitalization of approximately SGD1.85 billion. Operations: The primary revenue stream for UOB-Kay Hian Holdings comes from its Securities and Futures Broking and Related Services, generating approximately SGD631.69 million. UOB-Kay Hian Holdings, a smaller player in the financial sector, showcases robust financial health with a debt-to-equity ratio that has decreased from 75% to 43.8% over five years. The company's earnings growth of 11.7% annually over the same period underscores its potential, although it trails behind the Capital Markets industry's recent pace. With a price-to-earnings ratio of 8.3x, UOB-Kay Hian is attractively valued compared to Singapore's market average of 12.6x. Despite not being free cash flow positive, its profitability ensures that cash runway isn't an issue for this promising firm in Asia's dynamic landscape. Click to explore a detailed breakdown of our findings in UOB-Kay Hian Holdings' health report. Learn about UOB-Kay Hian Holdings' historical performance. Simply Wall St Value Rating: ★★★★★☆ Overview: Xiamen Leading Optics Co., Ltd. offers optical solutions globally and has a market cap of CN¥9.65 billion. Operations: The primary revenue stream for Xiamen Leading Optics comes from its optical manufacturing segment, generating CN¥640.46 million. Xiamen Leading Optics, a relatively smaller player in the electronics sector, has shown impressive financial strides. Over the past year, its earnings surged by 24.9%, outpacing the industry average of 2.7%. The company reported a notable increase in net income for Q1 2025 at CNY 56.87 million compared to CNY 34.3 million last year, alongside basic earnings per share rising to CNY 0.1397 from CNY 0.0844. Despite an increased debt-to-equity ratio from zero to 3.6% over five years, it maintains more cash than total debt and continues generating positive free cash flow, reflecting robust financial health and operational efficiency amidst market volatility. Dive into the specifics of Xiamen Leading Optics here with our thorough health report. Understand Xiamen Leading Optics' track record by examining our Past report. Unlock our comprehensive list of 2605 Asian Undiscovered Gems With Strong Fundamentals by clicking here. Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools. Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SEHK:8299 SGX:U10 and SHSE:605118. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
